Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open label, optimal 2-stage Simon design phase Ib-II clinical trial.
Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or
second-degree haploidentical donor are eligible for the study if they meet the standard
criteria defined in our institutional standard operation procedures (SOPs), meet all
inclusion criteria, and do not satisfy any exclusion criteria. Patients will receive
non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by
peripheral blood hematopoietic stem cells. Patients will receive cyclophosphamide, abatacept,
and short-duration tacrolimus for GvHD prophylaxis.